Anil Chandraker
Nephrology · Worcester, MANPI 1972569176
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $149,574 of the $161,909 with a category attached, or 92.4%. 15 manufacturers reported payments, led by Vertex at 57.7% of the total. 2025 is the largest year on record at $60,822, more than ten times the $1,050 reported in 2019. Among nephrology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 73 payments — averaging $2217.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$93K
- AstraZeneca$18K
- Sanofi-aventis U.S. LLC$16K
- Immucor, Inc.$11K
- Novartis$6K
- Sanofi US Services Inc.$6K
- plus $10K from 9 others
Across 65 payments — averaging $20,344 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$677K
- Amgen$519K
- Akebia Therapeutics Inc$86K
- Sanofi US Services Inc.$32K
- Shire North American Group Inc$8K
What the payments were for
- Consulting fees$149,57492%
- Speaking & faculty fees$2,6402%
- Travel & lodging$8,4005%
- Food & beverage$1,1891%
- Education$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 34 | $93,423 |
| AstraZeneca | 9 | $18,124 |
| Sanofi-aventis U.S. LLC | 4 | $16,439 |
| Immucor, Inc. | 2 | $11,048 |
| Novartis | 7 | $6,464 |
| Sanofi US Services Inc. | 3 | $6,233 |
| Amgen | 6 | $2,929 |
| Alnylam Pharmaceuticals Inc. | 1 | $2,700 |
| Calliditas Therapeutics US Inc. | 1 | $2,151 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,050 |
| Shire North American Group Inc | 1 | $1,050 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $211 |
| Biogen | 1 | $50 |
| Veloxis Pharmaceuticals, Inc. | 1 | $34 |
| Travere Therapeutics, Inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$161,909 in reported general payments places this provider in the 95th percentile of 339 nephrology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tacrolimus | 14 | $1,496 |
| Mycophenolic AcidMycophenolate Sodium | 11 | $1,439 |
| Metoprolol Succinate | 20 | $641 |
| Tamsulosin Hcl | 15 | $435 |
| Omeprazole | 11 | $285 |
| Prednisone | 33 | $260 |
| Lisinopril | 16 | $109 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $58 |
| Amlodipine Besylate | 14 | $49 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Worcester
- Matthew TrainorWorcester$26K
- David FriedmanBoston$19.8M
- Martin PollakBoston$19.8M
- Dennis AusielloBoston$4.6M
- Ajay SinghBoston$916K
- Michael GermainSpringfield$443K
- Rekha AbichandaniCambridge$442K
- Leslie FangBoston$388K
- Nicolaos AthienitesBrockton$294K
- Jean FrancisBoston$244K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.